Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CareRx Corp T.CRRX

Alternate Symbol(s):  CHHHF

CareRx Corporation is a Canada-based provider of pharmacy services to seniors living communities. The Company serves over 94,000 residents in over 1,500 senior and other congregate care communities, including long-term care homes, retirement homes, assisted living facilities, and group homes. It supports its home care partners by providing solutions for the supply of chronic medication. It offers a range of medication solutions. Its technology automates the preparation and verification of multi-dose compliance packaging of medication, providing the safety and adherence for individuals with complex medication regimes. Its network of pharmacy fulfillment centers delivers solutions for the supply of chronic medication and other specialty clinical pharmacy services. The Company provides services in rural and urban areas throughout Ontario, Alberta, British Columbia, and parts of Saskatchewan. It works with home operator partners to promote resident health, staff education and others.


TSX:CRRX - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Possibleidiot01on Mar 02, 2023 7:18pm
202 Views
Post# 35316397

Desjardins- more realistic? - cantechletter.com

Desjardins- more realistic? - cantechletter.com

CareRx has target trimmed by Desjardins

Desjardins Capital Markets analyst Gary Ho has lowered his target on pharmacy services company CareRx Corp (CareRx Stock Quote, Charts, News, Analysts, Financials TSX:CRRX), saying in a Thursday update that investors will need a little more patience, as a labour shortage in the healthcare space looks like a headwind that’ll be out front of CareRx at least over the near term. At the same time, Ho has maintained a “Buy” rating on the stock, saying CRRX is attractively undervalued at current levels.

 

Toronto-based CareRx provides pharmacy services to seniors living communities, currently serving over 93,000 residents in over 1,600 facilities, which include long-term care homes, retirement homes, assisted living facilities and group homes. 

The company is due to report fourth quarter 2022 financials on March 9, ahead of which Ho has forecasted revenue of $94.2 million and adjusted EBITDA of $7.1 million. 

Ho said CareRx continues to face challenges from above-normal vacancies, involving a longer fill time, a limited pool of candidates and higher turnover which adds to recruitment and training costs. The analyst maintained that the trouble is more pronounced for CareRx due to its institutional setting which requires more specifically trained staff and features a more competitive labour market.

Ho said CareRx’s vacancies have edged up since the holiday season.

“The shortages are most pronounced in pharmacy technicians, followed by pharmacy assistants (lower-salary positions that compete with other broader industries). CRRX is looking at creative avenues (eg bring people from retail or international pharmacists) but has not seen any signs of abatement,” Ho wrote.

 

As a result, Ho has lowered his margin estimates to 8.2 per cent in 2023 and 9.4 per cent in 2024.

“CRRX is in constructive discussions with the provinces to increase prices and improve funding, which if successful could alleviate some margin pressures,” he said.

By the numbers, Ho’s 2023 forecast now has CareRx’s revenue at $389 million compared to an estimated $382 million for 2022 and moving to $426 million for 2024. On earnings, adjusted EBITDA is expected to go from $32.2 million in 2022 to $31.8 million in 2023 and to $40.0 million in 2024.

CareRx’s share price has dropped significantly since mid-2021 highs, going from about $6.50 per share to now around $2.50.

With the update, Ho lowered his target from $5.00 to $4.50 per share, which at press time represented a projected one-year return of 87.5 per cent.


<< Previous
Bullboard Posts
Next >>